Macrocyclic compounds useful as inhibitors of kinases and HSP90
Disclosed are macrocyclic compounds of formulae I-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.
1. A method of treating a patient with a disease comprising administering to the patient with the disease an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt or solvate thereof;
wherein:
R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, nitro, cyano, alkyl, lower alkyl, substituted alkyl, alkenyl, alkynyl, alkylaryl, aralkyl, aryl, heteroalkyl, alkylheteroaryl, heterocyclyl, heteroaryl, OH, OR, NH 2 , N(R) 2 , SR, S(O)R, S(O) 2 R, —SO 2 N(R) 2 , —N(R)SO 2 R, —N(CO)R, —N(CO)N(R) 2 , —N(CO)OR, —O(CO)R, —(CO)R, —(CO)OR, —(CO)N(R) 2 , —O(CO)OR, or —O(CO)N(R) 2 , wherein each R can be the same or different;
when B 1 and B 2 together are —CH 2 —CH 2 —, then A 1 and A 2 together are —CH 2 —CH 2 —, or —CH═CH—; or when B 1 and B 2 together represent a covalent bond, then A 1 and A 2 together are —CH 2 —CH 2 —, —CH═CH—, —CH(OH)—CH(OH)—, —CH(OH)—CH(halogen)—, —CH(halogen)—CH(OH)—, or 1,2-cyclopropadiyl;
X 1 is hydrogen, halogen, OH, OR, NH 2 , N(R) 2 , NH—OR, SR, S(O)R, S(O) 2 R, —NH—O—(CH 2 ) n —CO 2 —R, —NH—O—(CH 2 ) n —CON(R) 2 ; or X 1 together with X 2 or X 3 represents a covalent bond, wherein each R can be the same or different;
X 2 and X 3 are both hydrogen, or one of X 2 and X 3 is hydrogen and the other together with X 1 represents a covalent bond;
X 4 and X 5 together are ═N—OR, ═N—O—(CH 2 ) n COOR, ═N—O—(CH 2 ) n CON(R) 2 , ═N—N(R) 2 , ═N—N—SOR or ═N—N—SO 2 R; or one of X 4 and X 5 is hydrogen and the other is O(CO)R, O(CO)OR, O(CO)N(R) 2 , —(CH 2 ) n C(O)OR, or —(CH 2 ) n C(O)N(R) 2 , and n is 0, 1, 2, or 3; or one of X 4 and X 5 together with X 6 represents a covalent bond and the other of X 4 and X 5 is OH, OR, O(CO)R, O(CO)OR, —N(R) 2 or O(CO)N(R) 2 , wherein each R can be the same or different;
X 6 is hydrogen or X 6 together with one of X 4 and X 5 represents a covalent bond; and
R is hydrogen, alkyl, lower alkyl, acyl, aryl, alkaryl, arylalkyl, heteroalkyl, heteroaryl, heterocyclyl, a protecting group; or two R on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclic or heteroaryl ring; and
n is 0, 1,2 or 3;
wherein the disease is a neurodegenerative disease or cancer.
2. The method of claim 1 , wherein the compound has the structure of Formula II:
wherein, R 7 is ═N—OR, ═N—O—(CH 2 ) n COOR, ═N—O—(CH 2 ) n CON(R) 2 , ═N—N(R) 2 , ═N—N—SOR or ═N—N—SO 2 R; and wherein each R can be the same or different.
3. The method of claim 2 , wherein R 1 is H, halogen or heterocyclyl.
4. The method of claim 2 , wherein R 5 is hydrogen, alkyl, aryl, heteroaryl or arylalkyl.
5. The method of claim 2 , wherein A 1 and A 2 together are —CH═CH—.
6. The method of claim 2 , wherein A 1 and A 2 together are —CH(OH)—CH(OH)—, —CH(OH)—CH(halogen)— or —CH(halogen)—CH(OH)—.
7. The method of claim 2 , wherein:
R 1 is H, Cl or heterocyclyl;
R 2 and R 4 are independently OH or OR;
R 5 is hydrogen, alkyl, aryl or aralkyl;
A 1 and A 2 together are —CH═CH— or —C(OH)—C(OH)—;
X 1 is hydrogen, halogen or NH—OR; and
R 7 is ═N—OR, ═N—O—(CH 2 ) n COOR, ═N—O—(CH 2 ) n CON(R) 2 , ═N—N(R) 2 , ═N—N—SOR, ═N—N—SO 2 R.
8. The method of claim 7 , wherein R 7 is ═N—OR, ═N—O—(CH 2 ) n COOR, or ═N—O—(CH 2 ) n CON(R) 2 .
9. The method of claim 2 , wherein:
R 1 is H, Cl or heterocyclyl;
R 2 and R 4 are independently OH or OR;
R 5 is hydrogen, alkyl, aryl or aralkyl;
A 1 and A 2 together are —CH═CH— or —C(OH)—C(OH)—;
X 1 together with X 2 represent a bond; and
R 7 is ═N—OR, ═N—O—(CH 2 ) n COOR, ═N—O—(CH 2 ) n CON(R) 2 , ═N—N(R) 2 , ═N—N—SOR, ═N—N—SO 2 R.
10. The method of claim 9 , wherein:
R 1 is H or Cl;
R 5 is hydrogen, methyl, propyl, isopropyl or phenyl; and
R 7 is ═N—OR, ═N—O—(CH 2 ) n COOR, or ═N—O—(CH 2 ) n CON(R) 2 .
11. The method of claim 10 , wherein R 1 is Cl and R 5 is hydrogen.
12. The method of claim 10 , wherein R 7 is ═N—O—(CH 2 ) n COOR, or ═N—O—(CH 2 ) n CON(R) 2 ; and n is 1.
13. The method of claim 10 , wherein R 5 is hydrogen and R 7 is ═N—O—(CH 2 ) n COOR, or ═N—O—(CH 2 ) n CON(R) 2 .
14. The method of claim 10 , wherein R 5 is hydrogen and R 7 is ═N—OR.
15. The method of claim 1 , wherein the compound is selected from the group consisting of
16. The method of claim 1 , wherein the disease is a neurodegenerative disease.
17. The method of claim 16 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Huntington's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.
18. The method of claim 1 , wherein the disease is a cancer.
19. The method of claim 18 , wherein the cancer is a cancer of breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, stomach, skin, lung, blood, bone, colon, pancreas, thyroid, sarcoma, bladder, liver, kidney, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity, pharynx, lip, tongue, mouth, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, or leukemia.
20. The method of claim 18 , wherein the cancer is breast cancer, lung cancer, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, colon cancer, liver cancer, stomach cancer, blood cancer, melanoma, or glioblastoma.
21. The method of claim 1 , wherein R is benzyl.